全文获取类型
收费全文 | 1197篇 |
免费 | 70篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 27篇 |
妇产科学 | 6篇 |
基础医学 | 91篇 |
口腔科学 | 76篇 |
临床医学 | 138篇 |
内科学 | 344篇 |
皮肤病学 | 44篇 |
神经病学 | 40篇 |
特种医学 | 95篇 |
外科学 | 105篇 |
综合类 | 78篇 |
预防医学 | 95篇 |
眼科学 | 4篇 |
药学 | 59篇 |
1篇 | |
中国医学 | 19篇 |
肿瘤学 | 49篇 |
出版年
2022年 | 13篇 |
2021年 | 17篇 |
2020年 | 14篇 |
2019年 | 12篇 |
2018年 | 21篇 |
2017年 | 10篇 |
2016年 | 10篇 |
2015年 | 34篇 |
2014年 | 24篇 |
2013年 | 41篇 |
2012年 | 47篇 |
2011年 | 49篇 |
2010年 | 47篇 |
2009年 | 36篇 |
2008年 | 41篇 |
2007年 | 60篇 |
2006年 | 45篇 |
2005年 | 41篇 |
2004年 | 29篇 |
2003年 | 46篇 |
2002年 | 28篇 |
2001年 | 31篇 |
2000年 | 22篇 |
1999年 | 29篇 |
1998年 | 29篇 |
1997年 | 31篇 |
1996年 | 34篇 |
1995年 | 25篇 |
1994年 | 25篇 |
1993年 | 17篇 |
1992年 | 27篇 |
1991年 | 20篇 |
1990年 | 26篇 |
1989年 | 38篇 |
1988年 | 47篇 |
1987年 | 35篇 |
1986年 | 24篇 |
1985年 | 20篇 |
1984年 | 25篇 |
1983年 | 12篇 |
1982年 | 11篇 |
1981年 | 5篇 |
1980年 | 11篇 |
1979年 | 5篇 |
1978年 | 7篇 |
1977年 | 6篇 |
1976年 | 10篇 |
1975年 | 5篇 |
1974年 | 5篇 |
1973年 | 6篇 |
排序方式: 共有1274条查询结果,搜索用时 8 毫秒
51.
S O Gottlieb P Ouyang S C Achuff K L Baughman T A Traill E D Mellits M L Weisfeldt G Gerstenblith 《Journal of the American College of Cardiology》1984,4(2):382-388
Reports of acute ischemic events after withdrawal of calcium antagonist therapy in outpatients and during bypass surgery in patients with prior angina at rest prompted the examination of the effect of nifedipine withdrawal in 81 patients who had completed a prospective, double-blind randomized trial of nifedipine versus placebo for rest angina. Thirty-nine patients underwent bypass surgery for uncontrolled angina or left main coronary artery disease. No significant difference between patients withdrawn from nifedipine or placebo was seen in the incidence of perioperative myocardial infarction, hypotension requiring intraaortic balloon counterpulsation, vasopressor or vasodilator requirements or incidence of significant arrhythmias. An additional 42 patients had completed 2 years on a protocol consisting of nitrates and propranolol in addition to nifedipine or placebo. During a mean of 66 hours of continuous monitoring after withdrawal of nifedipine or placebo, heart rate and blood pressure were unchanged. A worsening of previously present angina at rest occurred in five patients who had continued to experience rest angina before drug withdrawal, four of whom were withdrawn from nifedipine. No patient with class I to III angina experienced new onset of rest angina during drug withdrawal. No patient experienced myocardial infarction. There was no significant difference between patients withdrawn from nifedipine or placebo in the duration or frequency of ischemic ST changes on continuous electrocardiographic monitoring, or in duration or positive results of serial exercise treadmill testing. Thus, no early adverse effects of acute nifedipine withdrawal were found in patients with prior rest angina at the time of bypass surgery or in stable patients receiving long-term medical therapy.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
52.
53.
目的研究臂丛神经损伤膈神经移位术对青壮年患者早期呼吸功能的影响.方法对16例接受膈神经移位治疗的患者,在术前、术后(10 d)进行肺功能指标的比较,同时定期进行门诊随访,观察呼吸系统自觉症状程度.结果13例术后出现了不同程度的供氧不足症状,16例全部出现一侧膈肌抬高,术后第10天肺活量(VC)、肺活量预计值百分数(VC%)分别比术前减少37.98%和26.88%,两者差异有统计学意义(tvc=11.532、tvc%=0,P<0.01).其它项目如残气量(RV)较术前轻度下降,肺总量(TLC)下降值达到术前肺总量的36.49%,残气量/肺总量比值(RV/TLC%)较术前上升了4.75%,上述各指标的差值均有统计学意义.1 s用力呼气量/用力肺活量比值(FEV1/FVC)和术前比基本无改变,但其差值有统计学意义.膈神经移位右侧(10例)与左侧(6例)术前、术后肺活量比较差异有统计学意义.术后随访8个月~2年,所有患者均无明显呼吸困难和胸闷等症状.结论膈神经移位术后对青壮年患者肺容量有较大的丧失,肺通气功能减弱和小气道阻力增加,但其丧失程度在机体自身代偿耐受范围内,不会导致急剧发生的严重呼吸功能障碍.建议对右侧臂丛神经根性损伤的患者,术前进行严格的肺、心功能检查,避免发生较为严重的并发症. 相似文献
54.
目的:性治疗法目前尚未普及,本研究旨在评价性治疗法联合西地那非治疗勃起功能障碍(ED)的疗效。方法:根据治疗方法的不同将在本院治疗随访过的3130例维吾尔族ED患者分成2组。对照组625例,单纯口服西地那非3个月;试验组2505例,采用性治疗法联合西地那非治疗3个月。采用国际勃起功能问卷表(IIEF-5)在各组治疗前、后进行疗效评估,并随访12个月。结果:对照组治疗前、后及在6个月、12个月随访的IIEF-5评分分别为12.80±3.76、18.10±2.61、17.35±2.73和16.64±2.63;试验组治疗前、后及在6个月、12个月随访的IIEF-5评分分别为12.73±3.52、19.06±4.07、19.86±2.42和20.47±2.38。两组治疗前后IIEF-5评分自身对比差异均有显著性(P<0.05)。组间比较,试验组较对照组6个月和12个月随访IIEF-5评分均有显著性差异(P<0.05)。结论:性治疗法联合西地那非治疗ED的效果优于单纯西地那非治疗,并在12个月的随访中稳定性良好。 相似文献
55.
We defined erythropoietin (EPO) resistance by the ratio of the weekly EPO dose to hematocrit (Hct), yielding a continuously distributed variable (EPO/Hct). EPO resistance is usually attributed to iron or vitamin deficiency, hyperparathyroidism, aluminum toxicity, or inflammation. Activation of the acute-phase response, assessed by the level of the acute-phase C-reactive protein (CRP), correlates strongly with hypoalbuminemia and mortality in both hemodialysis (HD) and peritoneal dialysis (PD) patients. In this cross-sectional study of 92 HD and 36 PD patients, we examined the contribution of parathyroid hormone (PTH) levels, iron indices, aluminum levels, nutritional parameters (normalized protein catabolic rate [PCRn]), dialysis adequacy (Kt/V), and CRP to EPO/Hct. Albumin level serves as a measure of both nutrition and inflammation and was used as another independent variable. Serum albumin level (deltaR2 = 0.129; P < 0.001) and age (deltaR2 = 0.040; P = 0.040) were the best predictors of EPO/Hct in HD patients, and serum albumin (deltaR2 = 0.205; P = 0.002) and ferritin levels (deltaR2 = 0.132; P = 0.015) in PD patients. When albumin was excluded from the analysis, the best predictors of EPO/Hct were CRP (deltaR2 = 0.105; P = 0.003) and ferritin levels (deltaR2 = 0.051; P = 0.023) in HD patients and CRP level (deltaR2 = 0.141; P = 0.024) in PD patients. When both albumin and CRP were excluded from analysis in HD patients, low transferrin levels predicted high EPO/Hct (deltaR2 = 0.070; P = 0.011). EPO/Hct was independent of PTH and aluminum levels, PCRn, and Kt/V. High EPO/Hct occurred in the context of high ferritin and low transferrin levels, the pattern expected in the acute-phase response, not in iron deficiency. In well-dialyzed patients who were iron replete, the acute-phase response was the most important predictor of EPO resistance. 相似文献
56.
57.
58.
59.
Bradley D Baughman RP Raymond L Kaufman AH 《Seminars in respiratory and critical care medicine》2002,23(6):543-548
Ophthalmic involvement in sarcoidosis may cause significant sight-threatening illness for patients. Studies of patients with histologically proven sarcoidosis have found 25 to 50% of patients to have ocular manifestations. The frequency in which eye disease is seen and the course that it takes vary with age, race, and geography. This article discusses relevant aspects of the ocular manifestations of sarcoidosis for the internist and pulmonologist. Overall disease presentation, specific types of ocular involvement, evaluation strategies, and treatment considerations are discussed. 相似文献
60.